The American Society of Clinical Oncology (ASCO) conference was held in Orlando this year from June 3-7. This is the preeminent clinical cancer conference in the world with over 30,000 attendees.  Our reporters were at the conference and have provided summaries of significant sessions/posters including trials for axitinib and tivozanib, two therapies that are likely to be approved for use in metastatic kidney cancer. Click ASCO 2011.